Abstract
As we approach the completion of the first 25 years of the human immunodeficiency virus (HIV) epidemic, there have been dramatic improvements in the care of patients with HIV infection. These have prolonged life and decreased morbidity. There are twenty currently available antiretrovirals approved in the United States for the treatment of this infection. The medications, including their pharmacokinetic properties, side effects, and dosing are reviewed. In addition, the current approach to the use of these medicines is discussed. We have included a section addressing common comorbid conditions including hepatitis B and C along with tuberculosis.
MeSH terms
-
Anti-Retroviral Agents / pharmacology
-
Anti-Retroviral Agents / therapeutic use*
-
Antiretroviral Therapy, Highly Active / adverse effects*
-
Drug Resistance, Viral / genetics
-
Enfuvirtide
-
Female
-
Genotype
-
HIV Envelope Protein gp41 / pharmacology
-
HIV Envelope Protein gp41 / therapeutic use
-
HIV Fusion Inhibitors / pharmacology
-
HIV Fusion Inhibitors / therapeutic use
-
HIV Infections / complications
-
HIV Infections / drug therapy*
-
HIV Infections / genetics
-
Hepatitis B / complications
-
Hepatitis B / drug therapy
-
Humans
-
Mutation
-
Peptide Fragments / pharmacology
-
Peptide Fragments / therapeutic use
-
Practice Guidelines as Topic
-
Pregnancy
-
Pregnancy Complications, Infectious / drug therapy*
-
Pregnancy Complications, Infectious / genetics
-
Protease Inhibitors / pharmacology
-
Protease Inhibitors / therapeutic use
-
Reverse Transcriptase Inhibitors / pharmacology
-
Reverse Transcriptase Inhibitors / therapeutic use
-
Ritonavir / pharmacology
-
Ritonavir / therapeutic use
-
Zidovudine / pharmacology
-
Zidovudine / therapeutic use
Substances
-
Anti-Retroviral Agents
-
HIV Envelope Protein gp41
-
HIV Fusion Inhibitors
-
Peptide Fragments
-
Protease Inhibitors
-
Reverse Transcriptase Inhibitors
-
Enfuvirtide
-
Zidovudine
-
Ritonavir